Blood Pressure Control and Its Determinants among Patients with Chronic Kidney Disease in a Nigerian Tertiary Hospital: A Cross-Sectional Study https://doi.org/10.60787/NMJ-63-5-140
Main Article Content
Keywords
Blood Pressure, Control, Chronic Kidney Disease
Abstract
Background: Hypertension is a common cardiovascular risk factor associated with adverse renal and cardiovascular outcomes in chronic kidney disease patients. Significant reduction in these adverse outcomes could be achieved through adequate blood pressure control in those with hypertension. This study aimed to determine the prevalence of poor blood pressure control and associated factors among chronic kidney disease patients with hypertension in a Nigerian tertiary hospital.
Methodology: This was a cross-sectional study that determined the prevalence of poor blood pressure control and its associated factors among chronic kidney disease patients with hypertension. Poor blood pressure control was defined as blood pressure ≥ 140/90mmHg. Factors associated with blood pressure control were determined by multivariate analysis. A P-value less than 0.05 was considered significant.
Results: A total of 494 chronic kidney disease patients with hypertension were studied. The mean age of patients was 48.77+13.06, with a range of 17-95 years. There were 303 (61.3%) males and 191 (38.7%) females. A total of 44.5% of the patients had end-stage renal disease, while all patients were on antihypertensive medications. The common causes of chronic kidney disease were hypertension (35%), diabetes mellitus (26.5%), and chronic glomerulonephritis (12.1%). Poor blood pressure control was found in 74.4% of chronic kidney disease patients. The predictors of poor blood pressure control were age (AOR: 0.65; CI: 0.45-0.94; p=0.02), use of multiple anti-hypertensives (AOR: 1.99; CI: 1.36-2.90; p=<0.001) and the presence of significant proteinuria (AOR: 1.47; CI: 1.02-2.14; p=0.04).
Conclusion: The majority of patients with chronic kidney disease had poor blood pressure control. Those who were young had significant proteinuria, and those who used≥ 3 antihypertensive medications were more likely to have poor blood control. There is a need to optimize BP management in chronic kidney disease patients to reduce adverse outcomes.
References
2.Schrauben SJ, Chen HY, Lin E, Jepson C, Yang W, Scialla JJ et al; CRIC Study Investigators. Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. PLoS Med. 2020;17:e1003470.doi: 10.1371/journal.pmed.1003470.
3.Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int.1995; 47:186–92
4.Adejumo OA, Okaka EI, Madumezia G, Okwuonu CG, Ojogwu LI. Assessment of some cardiovascular risk factors in predialysischronic kidney disease patients in Southern Nigeria. Niger Med J. 2015; 56:394-9.
5.Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Archives of internal medicine. 2006;166:1884-91.
6.Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G et al; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis.2010; 55:441-51.
7.Naicker S. End-stage renal disease in Sub-Saharan Africa. Kidney InternationalSupplements. 2013;3:161-3.
8.Sui Z, Wang J, Cabrera C, Wei J, Wang M, Zuo L. Aetiology of chronic kidney disease and risk factors for disease progression in Chinese subjects: A single-centre retrospective study inBeijing. Nephrology (Carlton). 2020 Sep; 25:714-722
9.Ulasi II, Arodiwe EB, Ijoma CK. Left ventricular hypertrophy in African black patients with chronic renal failure at first evaluation. Ethn Dis. 2006; 16:859–64
10.Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. American Journalof Kidney Diseases. 2019;74:120-31.
11.Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. Clinical and experimentalnephrology. 2019;23:85-98.
12.Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996; 49:1379-85.
13.Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE et al; KEEP Investigators. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). ArchIntern Med. 2012;172:41-47.
14.Lee YB, Lee JS, Hong SH, Kim JA, Roh E, Yoo HJ et al. Optimal blood pressure for patients with chronic kidney disease: a nationwide population-based cohort study. ScientificReports.2021;11.https://doi.org/10.1038/s41598-021-81328-y
15.Bansal N, McCulloch CE, Rahman M, Kusek JW, Anderson AH, Xie D et al. Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension. 2015;65:93-100.
16.Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967.
17.Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185:949-57.
18.Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMAinternal medicine. 2017;177:1498-505.
19.McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can J Cardiol.2006; 22:855-60
20.Okaka EI, Ojeh-Oziegbe OE, Unuigbe EI. Factors associated with blood pressure control in predialysis chronic kidney disease patients: short-term experience from a single center in Southern Nigeria. Niger J ClinPract2017; 20:537-41.
21.Chow CK, Gupta R. Blood pressure control: a challenge to global health systems. The Lancet.2019; 394:613-5
22.Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ et al Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC FamPract. 2013; 14:88. doi: 10.1186/1471-2296-14-88
23.Mancia G, Fagard R, Narkiewicz K, Redon J,Zanchetti A, Böhm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219
24.Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med.2009 May 5; 150:604-12. doi: 10.7326/0003-4819-150-9-200905050-00006. Erratum inAnn Intern Med. 2011;155:408.
25.Kidney DiseasesImproving Global Outcome (KDIGO) 2012 Clinical Practice Guideline of evaluation and management of CKD. KidneyInt Supplements. 2013;3:1–150
26.International Labour Office, Geneva, International Standard Classification of Occupation ICSO-08. Volume 1. Structure, group definitions and correspondence tables. Available @http://www.ilo.org.public. Last accessed 27thJuly 2022.
27.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–97.
28.McClellan W, Aronoff SL, Kline Bolton W, Hood S, Lorber DL, Tang KL.The prevalence of anaemia in patients with chronic kidney disease. Curr Med Res Opin2004; 20:1501-10.
29.Goldstein DA. Serum Calcium. In: Walker HK,Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examina tions. 3rd edition. Boston:Butterworths; 1990. Chapter 143. Available from:https://www.ncbi.nlm.nih.gov/books/NB K250/
30.Goyal R, Jialal I. Hyperphosphatemia. In: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Availablef r o m : https://www.ncbi.nlm.nih.gov/books/NBK551 586/.
31.George C, Minter DA. Hyperuricemia. [Updated 2022 Jul 18]. In: StatPearls [Internet].Treasure Island (FL): StatPearls Publishing; 2 0 22 Jan -.Available from:https://www.ncbi.nlm.nih.gov/books/NBK459 218/
32.James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. Erratum in:JAMA. 2014;311:1809
33.Taslim BB, Oluwafemi OS. Self-reported medication adherence and blood pressure control rates in patients with chronic kidney disease. Afr J Med Health Sci2015; 14:61-5
34.Magvanjav O, Cooper DeHoff RM, McDonough CW, Gong Y, Segal MS, Hogan WR et al. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. The Journal of ClinicalHypertension. 2019;21:91-101.
35.Makusidi AM, Chijoke A, Rafiu MO, Okoro EO. Factors influencing level of blood pressure control in chronic kidney disease patients from Ilorin,Nigeria. Sahel Med J2011; 14:74-84.
36.Yan Z, Wang Y, Li S, Wang J, Zhang L, Tan H et al; China National Survey of Chronic Kidney Disease Working Group. Hypertension Control in Adults with CKD in China: Baseline Results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Am J Hypertens.2018; 31:486-494.
37.Peralta CA, Hicks LS, Chertow GM, Ayanian JZ, Vittinghoff E, Lin F et al Control of hypertension in adults with chronic kidney disease in the United States. Hypertension.2005; 45:1119-24.
38.Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99:S1-S87.
39.Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens.2020; 38:982-1004
40.SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373:2103-16 Erratum in: N Engl J Med. 2017; 377:2506.
41.Adejumo OA, Akinbodewa AA, Ogunleye A, Enikuomehin AC, Lawal OM. Cost implication of inpatient care of chronic kidney disease patients in a tertiary hospital in Southwest Nigeria. Saudi J Kidney Dis Transpl.2020; 31:209-214.
42.Ihm CG. Hypertension in Chronic Glomerulonephritis. Electrolyte Blood Press.2015;13:41-5.43.Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021;78:1197-205.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.